

Eva Kubala Havrdova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6961707/publications.pdf>

Version: 2024-02-01

296
papers

31,152
citations

10351

72
h-index

4628

170
g-index

319
all docs

319
docs citations

319
times ranked

18686
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis. <i>International Journal of Neuroscience</i> , 2022, 132, 724-734.	0.8	6
2	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , 2022, 29, 1082-1090.	1.7	11
3	The clinical and paraclinical correlates of employment status in multiple sclerosis. <i>Neurological Sciences</i> , 2022, 43, 1911-1920.	0.9	4
4	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 1670-1677.	1.8	39
5	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103389.	0.9	6
6	Pregnancy-induced brain magnetic resonance imaging changes in women with multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 1446-1456.	1.7	7
7	Steroid Sulfation in Neurodegenerative Diseases. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 839887.	1.6	13
8	Multiple Sclerosis Relapses Following Cessation of Fingolimod. <i>Clinical Drug Investigation</i> , 2022, 42, 355-364.	1.1	8
9	Time course of lesion-induced atrophy in multiple sclerosis. <i>Journal of Neurology</i> , 2022, 269, 4478-4487.	1.8	3
10	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339.	1.7	3
11	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2022, 28, 842-846.	1.4	13
12	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	12
13	Periventricular gradient of T1 tissue alterations in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2022, 34, 103009.	1.4	9
14	Flow Cytometry Analysis of Blood Large Extracellular Vesicles in Patients with Multiple Sclerosis Experiencing Relapse of the Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 2832.	1.0	2
15	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, , .	1.7	1
16	Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 220-231.	1.4	55
17	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021, 27, 479-482.	1.4	7
18	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	1.4	11

#	ARTICLE	IF	CITATIONS
19	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 52-60.	1.4	41
20	Interpretation of Brain Volume Increase in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 401-407.	1.0	6
21	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642098213.	1.5	30
22	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3
23	Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. <i>Diagnostics</i> , 2021, 11, 464.	1.3	9
24	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	15
25	Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review. <i>Frontiers in Neurology</i> , 2021, 12, 554375.	1.1	18
26	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.5	41
27	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. <i>JAMA Neurology</i> , 2021, 78, 558.	4.5	132
28	The potential of serum neurofilament as biomarker for multiple sclerosis. <i>Brain</i> , 2021, 144, 2954-2963.	3.7	98
29	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102844.	0.9	19
30	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880.	1.5	15
31	The effectiveness of natalizumab vs fingolimod – A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	0.9	8
32	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021, 357, 577627.	1.1	33
33	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180.	2.6	21
34	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
35	Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103187.	0.9	4
36	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54

#	ARTICLE	IF	CITATIONS
37	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2001-2013.	1.4	9
38	Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis. <i>Diagnostics</i> , 2021, 11, 2230.	1.3	2
39	Oral cladribine in the treatment of multiple sclerosis – data from the national registry ReMuS [®] registry. <i>Ceska A Slovenska Neurologie A Neurochirurgie</i> , 2021, 84/117, .	0.0	1
40	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	1.4	52
41	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	0.9	29
42	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6
43	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102534.	0.9	14
44	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. <i>JAMA Neurology</i> , 2020, 77, 1496.	4.5	21
45	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. <i>Journal of Clinical Lipidology</i> , 2020, 14, 675-684.e2.	0.6	8
46	Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFN β . <i>Frontiers in Immunology</i> , 2020, 11, 1527.	2.2	24
47	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.	4.5	21
48	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	3.7	24
49	Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642097522.	1.5	5
50	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	3.7	32
51	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2020, 9, 443-457.	1.4	4
52	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1045-1063.	1.4	21
53	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1031-1044.	1.4	39
54	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.	4.9	219

#	ARTICLE	IF	CITATIONS
55	Monitoring of radiologic disease activity by serum neurofilaments in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	24
56	Long-term safety and efficacy of daclizumab beta in relapsing remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. <i>Journal of Neurology</i> , 2020, 267, 2851-2864.	1.8	8
57	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	3.9	31
58	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1255-1262.	1.4	37
59	Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019, 10, 820.	1.1	16
60	PND68 COST-EFFECTIVENESS OF OCRELIZUMAB COMPARED TO FINGOLIMOD OR DMF IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CZECH REPUBLIC. <i>Value in Health</i> , 2019, 22, S282.	0.1	0
61	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1009-1020.	4.9	191
62	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1021-1033.	4.9	184
63	Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study. <i>Journal of Clinical Neuroscience</i> , 2019, 65, 28-33.	0.8	16
64	Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?. <i>Journal of Neural Transmission</i> , 2019, 126, 731-737.	1.4	3
65	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1273-1288.	1.4	29
66	A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. <i>American Journal of Neuroradiology</i> , 2019, 40, 446-452.	1.2	15
67	Real-Life Outcome in Multiple Sclerosis in the Czech Republic. <i>Multiple Sclerosis International</i> , 2019, 2019, 1-8.	0.4	6
68	Biofeedback Based Home Balance Training can Improve Balance but Not Gait in People with Multiple Sclerosis. <i>Multiple Sclerosis International</i> , 2019, 2019, 1-9.	0.4	8
69	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019, 326, 19-27.	1.1	22
70	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	0.9	71
71	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	0.9	35
72	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336

#	ARTICLE	IF	CITATIONS
73	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	1.7	12
74	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1605-1617.	1.4	57
75	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 541-553.	1.4	32
76	"The spectrum of MRI findings of progressive multifocal leukoencephalopathy in patients with multiple sclerosis in the Czech Republic". <i>Ceska A Slovenska Neurologie A Neurochirurgie</i> , 2019, 82/115, 381-390.	0.0	1
77	Neurorehabilitation of gait impairment using functional electrical stimulation – current findings from randomized clinical trials. <i>Ceska A Slovenska Neurologie A Neurochirurgie</i> , 2019, 82/115, 621-626.	0.0	0
78	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2018, 388, 87-93.	0.3	7
79	Establishing pathological cut-offs for lateral ventricular volume expansion rates. <i>NeuroImage: Clinical</i> , 2018, 18, 494-501.	1.4	26
80	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [<i>Mult. Scler. Relat. Disord.</i> (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 166.	0.9	0
81	Management of multiple sclerosis patients in central European countries: current needs and potential solutions. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875918.	1.5	17
82	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 105-108.	0.9	22
83	The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018, 28, 328-337.	1.0	4
84	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018, 141, 1085-1093.	3.7	115
85	Cognitive clinico-radiological paradox in early stages of multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 81-91.	1.7	26
86	<sc>ECTRIMS</sc>/<sc>EAN</sc> guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 215-237.	1.7	147
87	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 96-120.	1.4	458
88	Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management. <i>European Journal of Neurology</i> , 2018, 25, 739-746.	1.7	12
89	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731876064.	0.5	32
90	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , The, 2018, 17, 405-415.	4.9	238

#	ARTICLE	IF	CITATIONS
91	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	1.4	37
92	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1883-1891.	1.4	2
93	Cladribine versus fingolimod, natalizumab and interferon β 2 for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626.	1.4	36
94	Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 153-160.	0.9	101
95	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. <i>NeuroImage: Clinical</i> , 2018, 17, 444-451.	1.4	58
96	PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET. <i>Value in Health</i> , 2018, 21, S332.	0.1	0
97	060â€¦Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A25.1-A25.	0.9	0
98	Do eyes with and without optic neuritis in multiple sclerosis age equally?. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2281-2285.	1.0	5
99	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. <i>Annals of Neurology</i> , 2018, 84, 958-959.	2.8	10
100	044â€¦Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A18.2-A19.	0.9	0
101	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 11-19.	0.9	17
102	Monocyte NOTCH2 expression predicts IFN- β 2 immunogenicity in multiple sclerosis patients. <i>JCI Insight</i> , 2018, 3, .	2.3	46
103	Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 242-252.	1.4	39
104	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 94-105.	1.4	95
105	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 51-61.	1.4	39
106	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 253-265.	1.4	126
107	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	1.4	30
108	Survey of diagnostic and treatment practices for multiple sclerosis in Europe. <i>European Journal of Neurology</i> , 2017, 24, 516-522.	1.7	34

#	ARTICLE	IF	CITATIONS
109	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , 2017, 74, 459.	4.5	199
110	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	0.9	49
111	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	4.9	134
112	Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. <i>Autoimmunity Reviews</i> , 2017, 16, 658-665.	2.5	106
113	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-term Comparative Study. <i>Journal of Neuroimaging</i> , 2017, 27, 620-629.	1.0	20
114	Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. <i>European Journal of Neurology</i> , 2017, 24, 726-733.	1.7	50
115	No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1736-1747.	1.4	18
116	“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1179-1187.	1.4	126
117	MxA mRNA decrease preceding NAb detection in IFN β -treated MS patients. <i>Brain and Behavior</i> , 2017, 7, e00644.	1.0	1
118	Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 11, 18-24.	0.9	12
119	Serum lipid profile changes predict neurodegeneration in interferon- β 1a-treated multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2017, 58, 403-411.	2.0	43
120	Alemtuzumab CARE-MS I 5-year follow-up. <i>Neurology</i> , 2017, 89, 1107-1116.	1.5	188
121	Alemtuzumab CARE-MS II 5-year follow-up. <i>Neurology</i> , 2017, 89, 1117-1126.	1.5	232
122	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.5	38
123	timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, e1.11-e1.	0.9	0
124	New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic. <i>Multiple Sclerosis Journal</i> , 2017, 23, 41-52.	1.4	13
125	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2017, 15, 769-779.	1.4	48
126	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 32-40.	0.9	9

#	ARTICLE	IF	CITATIONS
127	Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1367-1376.	1.4	26
128	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	1.4	18
129	Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. <i>European Journal of Neurology</i> , 2017, 24, 292-301.	1.7	38
130	PO114â€¦Neda achievement by time interval with daclizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A42.1-A42.	0.9	0
131	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	3.7	94
132	PO129â€¦Neda analysis by epoch in the opera studies of ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A46.2-A46.	0.9	3
133	Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. <i>BMC Neurology</i> , 2017, 17, 145.	0.8	10
134	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1423-1437.	0.9	25
135	Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNÎ². <i>PLoS ONE</i> , 2017, 12, e0169957.	1.1	1
136	Fingolimod in Real Clinical Practice. <i>Ceska A Slovenska Neurologie A Neurochirurgie</i> , 2017, 80/113, 213-219.	0.0	0
137	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309690.	0.9	90
138	Daclizumab highâ€¦yield process reduced the evolution of new gadoliniumâ€¦enhancing lesions to T1 black holes in patients with relapsingâ€¦remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 412-415.	1.7	9
139	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	3.7	281
140	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 729-736.	1.7	21
141	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	0.9	63
142	Comparative efficacy of first-line natalizumab vs IFNÎ² or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 102-115.	0.8	33
143	Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 66-72.	0.9	18
144	Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. <i>Journal of Neurology</i> , 2016, 263, 1287-1295.	1.8	158

#	ARTICLE	IF	CITATIONS
145	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016, 87, 1985-1992.	1.5	55
146	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β -1a in MS. <i>Neurology</i> , 2016, 87, 1464-1472.	1.5	28
147	Reliable measurements of brain atrophy in individual patients with multiple sclerosis. <i>Brain and Behavior</i> , 2016, 6, e00518.	1.0	58
148	Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. <i>Neurology and Therapy</i> , 2016, 5, 169-182.	1.4	16
149	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. <i>BMC Neurology</i> , 2016, 16, 117.	0.8	40
150	Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.6	18
151	ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, e1.30-e1.	0.9	0
152	DACLIZUMAB HYP IN MULTIPLE SCLEROSIS: 3-YEAR RESULTS FROM SELECTED. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, e1.48-e1.	0.9	0
153	DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, e1.47-e1.	0.9	1
154	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	2.8	158
155	MENACTRIMS congress 2016. <i>Multiple Sclerosis Journal</i> , 2016, 22, NP1-NP24.	1.4	3
156	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 574-584.	4.9	266
157	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1709-1718.	1.4	69
158	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. <i>Multiple Sclerosis Journal</i> , 2016, 22, 770-781.	1.4	37
159	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	1.4	34
160	â€˜Hiddenâ€™ factors influencing quality of life in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 28-33.	1.7	48
161	ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.9-e4.	0.9	0
162	Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis. <i>Journal of the Neurological Sciences</i> , 2015, 357, e300-e301.	0.3	0

#	ARTICLE	IF	CITATIONS
163	Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. <i>Clinical and Experimental Immunology</i> , 2015, 181, 385-400.	1.1	72
164	Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. <i>Neurology and Therapy</i> , 2015, 4, 93-104.	1.4	80
165	MANAGEMENT OF ADVERSE REACTIONS TO ALEMTUZUMAB INFUSION. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.23-e4.	0.9	1
166	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	2.8	143
167	Natalizumab improves ambulation in relapsingâˆ“remitting multiple sclerosis: results from the prospective <scp>TIMER</scp> study and a retrospective analysis of <scp>AFFIRM</scp>. <i>European Journal of Neurology</i> , 2015, 22, 570-577.	1.7	16
168	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	1.4	249
169	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. <i>Neurology</i> , 2015, 84, 1145-1152.	1.5	63
170	Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 31-45.	1.5	134
171	Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 202-218.	0.9	85
172	Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5). <i>Journal of NeuroEngineering and Rehabilitation</i> , 2015, 12, 14.	2.4	53
173	Early magnetic resonance imaging predictors of clinical progression after 48Âmonths in clinically isolated syndrome patients treated with intramuscular interferon Î²â€“1a. <i>European Journal of Neurology</i> , 2015, 22, 1113-1123.	1.7	25
174	<scp>BREMSO</scp>: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 981-989.	1.7	32
175	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	4.5	100
176	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. <i>Journal of Lipid Research</i> , 2015, 56, 2010-2018.	2.0	45
177	Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 624-632.	1.7	17
178	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2015, 373, 1418-1428.	13.9	245
179	Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. <i>American Journal of Neuroradiology</i> , 2015, 36, 1457-1464.	1.2	13
180	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162

#	ARTICLE	IF	CITATIONS
181	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. <i>Clinical Therapeutics</i> , 2015, 37, 2543-2551.	1.1	9
182	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	1.4	36
183	Increased Serum Levels of C21 Steroids in Female Patients With Multiple Sclerosis. <i>Physiological Research</i> , 2015, 64, S247-S254.	0.4	7
184	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2015, 17, 236-243.	0.4	47
185	Neuromyelitis Optica Spectrum Disorders – Retrospective Analysis of Clinical and Paraclinical Findings. <i>Ceska A Slovenska Neurologie A Neurochirurgie</i> , 2015, 78/111, 72-77.	0.0	2
186	The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalus. <i>Neuroendocrinology Letters</i> , 2015, 36, 564-71.	0.2	14
187	Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 464-470.	1.4	25
188	MRI correlates of disability progression in patients with CIS over 48 months. <i>NeuroImage: Clinical</i> , 2014, 6, 312-319.	1.4	39
189	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. <i>Journal of the Neurological Sciences</i> , 2014, 347, 229-234.	0.3	8
190	Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2014, 82, 573-581.	1.5	249
191	The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 1386.	4.5	45
192	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. <i>Journal of Neuroimmunology</i> , 2014, 273, 58-64.	1.1	21
193	A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 773-783.	1.8	168
194	Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 316-323.	1.8	18
195	Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. <i>Current Medical Research and Opinion</i> , 2014, 30, 613-627.	0.9	70
196	Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 253-257.	1.4	40
197	Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy. <i>Journal of Neuroimmunology</i> , 2014, 275, 63-64.	1.1	2
198	Should rapid decrease of NK cells be marker of conversion from CIS to CDMS?. <i>Journal of Neuroimmunology</i> , 2014, 275, 88.	1.1	0

#	ARTICLE	IF	CITATIONS
199	Complement activation in patients with neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2014, 274, 185-191.	1.1	54
200	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 424-433.	1.2	14
201	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 859-864.	0.9	35
202	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. <i>Journal of Neurology</i> , 2014, 261, 1735-1744.	1.8	45
203	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , 2014, 83, 1210-1216.	1.5	30
204	Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 513-519.	0.9	34
205	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. <i>Lancet Neurology</i> , The, 2014, 13, 472-481.	4.9	83
206	Future MS care: a consensus statement of the MS in the 21st Century Steering Group. <i>Journal of Neurology</i> , 2013, 260, 462-469.	1.8	27
207	Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 248.	4.5	13
208	An integrated analysis of relapses requiring intravenous steroid use and multiple sclerosis (MS)-related hospitalizations from the BG-12 (dimethyl fumarate) phase 3 define and confirm studies. <i>Value in Health</i> , 2013, 16, A101-A102.	0.1	2
209	Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (<sc>MS</sc>). <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 302-306.	1.9	11
210	Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2145-2156.	0.9	34
211	Oral BG-12 in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2013, 368, 1652-1653.	13.9	3
212	Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, S42-S48.	0.6	12
213	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2013, 381, 2167-2175.	6.3	269
214	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2013, 263, 121-127.	1.1	14
215	Gastrointestinal tolerability events in relapsing-remitting multiple sclerosis patients treated with BG-12 (dimethyl fumarate): Integrated analysis of DEFINE and CONFIRM. <i>Journal of the Neurological Sciences</i> , 2013, 333, e368-e369.	0.3	0
216	Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. <i>Genes and Immunity</i> , 2013, 14, 244-248.	2.2	18

#	ARTICLE	IF	CITATIONS
217	Leukocyte counts in cerebrospinal fluid and blood following fingolimod treatment in subjects with relapsing forms of multiple sclerosis. <i>European Journal of Neurology</i> , 2013, 20, 1032-1042.	1.7	8
218	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. <i>Journal of Neurology</i> , 2013, 260, 2286-2296.	1.8	68
219	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. <i>Radiology</i> , 2013, 268, 831-841.	3.6	145
220	Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years. <i>American Journal of Neuroradiology</i> , 2013, 34, 1931-1939.	1.2	90
221	Lipid profiles are associated with lesion formation over 24 months in interferon- β treated patients following the first demyelinating event. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1186-1191.	0.9	114
222	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. <i>Multiple Sclerosis International</i> , 2013, 2013, 1-8.	0.4	9
223	How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?. <i>Frontiers in Neurology</i> , 2013, 4, 10.	1.1	23
224	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. <i>PLoS ONE</i> , 2013, 8, e53996.	1.1	68
225	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Yes. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1209-1210.	1.4	2
226	Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2012, 33, 1573-1578.	1.2	133
227	Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis. <i>Neurological Research</i> , 2012, 34, 923-930.	0.6	7
228	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet</i> , 2012, 380, 1819-1828.	6.3	1,041
229	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet</i> , 2012, 380, 1829-1839.	6.3	1,040
230	Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. <i>Wiener Medizinische Wochenschrift</i> , 2012, 162, 354-366.	0.5	16
231	Restless legs syndrome in Czech patients with multiple sclerosis: An epidemiological and genetic study. <i>Sleep Medicine</i> , 2012, 13, 848-851.	0.8	38
232	PND58 Effects of BG-12 on Quality of Life in Relapsing-Remitting Multiple Sclerosis: Findings From the Phase 3 Confirm Study. <i>Value in Health</i> , 2012, 15, A556.	0.1	1
233	PND3 Relapses Requiring Intravenous Steroids and Multiple Sclerosis-Related Hospitalizations: Findings From the Phase 3 Define and Confirm Studies. <i>Value in Health</i> , 2012, 15, A546.	0.1	1
234	Cost of multiple sclerosis in the Czech Republic: The COMS study. <i>Multiple Sclerosis Journal</i> , 2012, 18, 662-668.	1.4	34

#	ARTICLE	IF	CITATIONS
235	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012, 18, 143-152.	1.4	220
236	Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 367, 1087-1097.	13.9	1,161
237	Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. <i>Multiple Sclerosis Journal</i> , 2012, 18, 314-321.	1.4	63
238	Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. <i>Clinical Neurology and Neurosurgery</i> , 2012, 114, 940-946.	0.6	18
239	Cross Cultural Validation of The Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). <i>Clinical Neuropsychologist</i> , 2012, 26, 1186-1200.	1.5	105
240	Corpus Callosum Atrophy – A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study. <i>European Neurology</i> , 2012, 68, 23-27.	0.6	32
241	Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study. <i>PLoS ONE</i> , 2012, 7, e50101.	1.1	73
242	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. <i>Journal of Neurology</i> , 2012, 259, 898-905.	1.8	66
243	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. <i>Lancet Neurology</i> , The, 2012, 11, 420-428.	4.9	152
244	Early predictors of non-response to interferon in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 390-397.	1.0	22
245	Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study (S01.003). <i>Neurology</i> , 2012, 78, S01.003-S01.003.	1.5	6
246	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	1.1	35
247	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. <i>Journal of Neuroimmunology</i> , 2011, 236, 76-80.	1.1	12
248	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. <i>Lancet Neurology</i> , The, 2011, 10, 745-758.	4.9	247
249	BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 449-456.	1.8	45
250	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011, 69, 292-302.	2.8	8,001
251	Freedom from disease activity in multiple sclerosis. <i>Neurology</i> , 2010, 74, S3-7.	1.5	125
252	Risks of Immune System Treatments. <i>Science</i> , 2010, 328, 825-826.	6.0	24

#	ARTICLE	IF	CITATIONS
253	High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. <i>Multiple Sclerosis Journal</i> , 2010, 16, 685-693.	1.4	77
254	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1360-1366.	1.4	53
255	Patients'™ Stratification and Correlation of Brain Magnetic Resonance Imaging Parameters with Disability Progression in Multiple Sclerosis. <i>European Neurology</i> , 2009, 61, 278-284.	0.6	10
256	Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 965-976.	1.4	77
257	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. <i>Lancet Neurology</i> , The, 2009, 8, 254-260.	4.9	430
258	Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. <i>Lancet Neurology</i> , The, 2009, 8, 1111-1119.	4.9	233
259	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , 2009, 256, 405-415.	1.8	193
260	Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2009, 282, 112-119.	0.3	84
261	Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. <i>Journal of Neurology</i> , 2008, 255, 1449-1463.	1.8	204
262	Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. <i>Annals of Neurology</i> , 2008, 63, 611-620.	2.8	171
263	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet</i> , The, 2008, 371, 2085-2092.	6.3	265
264	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. <i>Lancet</i> , The, 2008, 372, 1463-1472.	6.3	457
265	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 407-414.	0.9	73
266	Neurobiological aspects of depressive disorder and antidepressant treatment: role of glia. <i>Physiological Research</i> , 2008, 57, 151-164.	0.4	29
267	Regulation of heme degradation in association with multiple sclerosis. <i>FASEB Journal</i> , 2008, 22, 1013.3.	0.2	0
268	Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. <i>International Review of Neurobiology</i> , 2007, 79, 475-489.	0.9	25
269	The incidence and significance of anti-natalizumab antibodies. <i>Neurology</i> , 2007, 69, 1391-1403.	1.5	312
270	Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. <i>Neurology</i> , 2007, 68, 1299-1304.	1.5	123

#	ARTICLE	IF	CITATIONS
271	MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. <i>Neurology</i> , 2007, 68, 1390-1401.	1.5	307
272	Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. <i>Current Medical Research and Opinion</i> , 2007, 23, 2823-2832.	0.9	7
273	Health-related quality of life in multiple sclerosis: effects of natalizumab. <i>Annals of Neurology</i> , 2007, 62, 335-346.	2.8	172
274	Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. <i>Lancet Neurology</i> , The, 2007, 6, 431-441.	4.9	331
275	Natalizumab in the Treatment of Patients with Multiple Sclerosis: First Experience. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 465-473.	1.8	6
276	Neutralising antibodies to interferon β in multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 827-837.	1.8	48
277	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2006, 354, 899-910.	13.9	2,916
278	A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. <i>European Journal of Neurology</i> , 2006, 13, 61-71.	1.7	46
279	Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. <i>Multiple Sclerosis Journal</i> , 2006, 12, 814-823.	1.4	206
280	Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms. <i>Multiple Sclerosis Journal</i> , 2006, 12, 108-111.	1.4	4
281	Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis. <i>Archives of Neurology</i> , 2006, 63, 614.	4.9	81
282	Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spirometric parameters in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 227-234.	1.4	82
283	Infusion-related hypersensitivity reactions during natalizumab treatment. <i>Neurology</i> , 2006, 67, 1717-1718.	1.5	47
284	Aggressive multiple sclerosis – is there a role for stem cell transplantation?. <i>Journal of Neurology</i> , 2005, 252, iii34-iii37.	1.8	10
285	Is it possible to actively and purposely make use of plasticity and adaptability in the neurorehabilitation treatment of multiple sclerosis patients? A pilot project. <i>Clinical Rehabilitation</i> , 2005, 19, 170-181.	1.0	32
286	Therapeutic Considerations for Disease Progression in Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 1519-30.	4.9	36
287	Spirometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2005, 11, 213-221.	1.4	29
288	Immunoablative Therapy with Autologous Stem Cell Transplantation in the Treatment of Poor Risk Multiple Sclerosis.. <i>Blood</i> , 2005, 106, 5519-5519.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Treatment optimization in multiple sclerosis: report of an international consensus meeting. <i>European Journal of Neurology</i> , 2004, 11, 43-47.	1.7	29
290	Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. <i>Clinica Chimica Acta</i> , 2004, 348, 147-154.	0.5	22
291	Myelin basic protein in multiple sclerosis and other neurological disorders. <i>Journal of Neurology</i> , 2003, 250, 874-875.	1.8	0
292	Hematopoietic stem cell transplantation for multiple sclerosis. <i>Journal of Neurology</i> , 2002, 249, 1088-1097.	1.8	230
293	Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. <i>Transplantation Proceedings</i> , 2001, 33, 2179-2181.	0.3	29
294	High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. <i>Bone Marrow Transplantation</i> , 2000, 25, 525-531.	1.3	94
295	Atrophy of caudate nucleus in Huntington's disease measured by computed tomography. <i>Journal of Neurology</i> , 2000, 247, 880-881.	1.8	2
296	Occurrence of IgA and IgG Autoantibodies to Calreticulin in Coeliac Disease and Various Autoimmune Diseases. <i>Journal of Autoimmunity</i> , 2000, 15, 441-449.	3.0	52